You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 204461 - 204470 of 207699 results
  1. Monoclonal Antibodies for the Treatment and Prevention of Enterovirus D68 Infection

    SBC: IDBIOLOGICS INC            Topic: 85

    The long-term objective of this work is to develop a monoclonal antibody product for the prevention and treatment of EV-D68 respiratory disease and acute flaccid myelitis (AFM). EV- 68 is an emerging picornavirus that has caused outbreaks of respiratory disease and is associated with AFM, which is a polio-like illness. The peak incidence of EV-D68 infections is August to October every other year s ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Adaptable RNA-based antibody platform for protection against contemporary /emerging human enteroviruses

    SBC: HDT BIO CORP            Topic: 85

    Enterovirus D68 (EVD68), a member of the Enterovirus genus, has become increasingly associated with alarming cases of acute flaccid myelitis in children and neonates across the United States. Additionally, EVD68 causes severe repiratory disease, especially in children with asthma, resulting in high rates of admittance to intensive care units with many patients requiring mechanical ventilation. The ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. EAP-DERIVED MONOCLONAL ANTIBODIES FOR PHENOTYPING GUINEA PIG IMMUNE CELLS.

    SBC: SILVER LAKE RESEARCH CORPORATION            Topic: 83

    The investigation of infectious disease mechanisms, treatments, and vaccines relies on animal models. Non-traditional animal models – such as the guinea pig model of tuberculosis - suffer from a lack of reagents, notably monoclonal antibodies (MAbs), used for characterizing subsets of immune cells and the cytokines they produce. For the guinea pig, a list of 25 high-priority targets has been com ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. AFFINITY REAGENTS FOR THE IMMUNE SYSTEM OF GUINEA PIGS

    SBC: QOOLABS INC            Topic: 83

    Guinea pigs have been used as experimental animals for centuries. Due to their biological similarities to humans, guinea pigs were used in many fields of biomedical research, such as nutritional research, vaccine research and development, hormonal studies, auditory system studies, and infectious disease studies. The usefulness of guinea pig as a small animal model for biomedical research has been ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. COMPREHENSIVE REAGENTS FOR IMMUNOPHENOTYPING RABBIT CELL-MEDIATED IMMUNITY.

    SBC: ABTERRA BIOSCIENCES, INC.            Topic: 83

    Infectious disease studies in tuberculosis and papillomavirus have shown humans and rabbits share similar pathology and rabbits are more phylogenetically similar to primates than rodents. The use of the rabbit model is hindered by the lack of species-specific immunological reagents. In this proposal, we will take a rational approach to generate the most critical reagents that are essential for sor ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. THE OBJECTIVE OF THIS CONTRACT IS TO ADAPT THE IPDA FOR THE MEASUREMENT OF LATENT HIV-1 FOR INDIVIDUALS WITH HIV-1 VIRAL GENETIC SUBTYPE CRF-1_AE.

    SBC: ACCELEVIR DIAGNOSTICS LLC            Topic: 78

    Human immunodeficiency virus type-1 (HIV-1) is a retrovirus that infects CD4+ T cells of the immune system. If left untreated, HIV-1 infected individuals will progress to AIDS and may ultimately die as a result. Current antiretroviral therapy is able to suppress HIV-1 replication, but it does not cure the infection. This is because HIV-1 persists in a stable and quiescent DNA form integrated into ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. PRODUCTION OF SYNTHETIC ADJUVANT SYSTEM (SAS): A SYNERGISTIC COMBINATION OF SYNTHETIC ADJUVANT COMPONENTS

    SBC: INIMMUNE CORP            Topic: 82

    There are very few FDA approved adjuvants available, limiting the discovery and development of vaccines to combat new pathogens that threaten public health. Inimmune Corp has developed a fully synthetic TLR4 agonist, INI-2002, with superior potency and stability versus other licensed TLR4 adjuvants. Simultaneously, Adjuvance Technologies has developed TQL-1055, a semi-synthetic and less toxic form ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  8. DEVELOPMENT OF FERRET REAGENTS FOR USE IN THE CHARACTERIZATION OF IMMUNE RESPONSES TO RESPIRATORY INFECTIONS IN THE FERRET MODEL.

    SBC: AMPERSAND BIOSCIENCES LLC            Topic: 83

    This proposal addresses a pressing need to develop reagents to better understand and describe the immune response to infection and support biomarker and countermeasure development through immunologic analyses of respiratory infections in the ferret. Select ferret-specific immunoreagents will be generated and tested in the context of influenza infection, where the ferret is considered to be the gol ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. TOPIC 377: SYMPTOM MANAGEMENT AND INTERVENTION ROADMAPS (STAIRS) (MOONSHOT) PHASE II

    SBC: CAREVIVE SYSTEMS INC            Topic: 377

    Numerous adverse symptoms are under-detected in cancer care resulting1-3 in missed opportunities for intervention; leading to poor treatment adherence, avoidable hospitalizations, and worse morbidity and survival. The IOM proposed shaking up the current symptom paradigm from reactive to proactive, personalized, technology-enabled models of symptom care as a solution to this clinical quality crisis ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  10. My Skills Coach Building Competency Pak: A Self-Regulating Tool for Individuals with an Intellectual Disability with Co-occurring Behavioral Health Issues

    SBC: CREATEABILITY CONCEPTS INC            Topic: NIDILRR

    This Phase II project builds upon previous research to further develop the My Skills Coach (MSC) application to create a competency pack of self-regulating tools for individuals with an intellectual disability (ID) and co-occurring behavioral health (BH) issues and their support staff. The MSC app portion of the Building Competency Pak assists consumers in building their personal self-regulation s ...

    SBIR Phase II 2021 Department of Health and Human ServicesAdministration for Community Living
US Flag An Official Website of the United States Government